Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 22.214.171.124) - Drugs in Development, 2021
Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 126.96.36.199) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels. It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 188.8.131.52) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Respiratory which include indications Hematological Tumor, Prostate Cancer, Solid Tumor, Diffuse Large B-Cell Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Peanut Allergy, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Triple-Negative Breast Cancer (TNBC).
The latest report SerineThreonine Protein Kinase Pim 1 - Drugs in Development, 2021, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 18.104.22.168) - The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 22.214.171.124) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 126.96.36.199) targeted therapeutics and enlists all their major and minor projects - The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 188.8.131.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 184.108.40.206) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 18.104.22.168) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 22.214.171.124) - Drugs in Development, 2021 Summary Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 126.96.36.199) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor...
“MB-102 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Blastic Plasmacytoid Dendritic Cell Neoplasm in 7 Major Markets. A detailed picture of the MB-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and...
Cancer Pain - Pipeline Review, H2 2020
latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.
Cancer pain can be defined as a complex sensation that...
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...
Catenin Beta 1 - Pipeline Review, H2 2020
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline...
426 pages •
By Roots Analysis Private Ltd.
• Nov 2020
INTRODUCTION Since the success of ADCETRIS® (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies...
Matrix Metalloproteinase 9 - Pipeline Review, H2 2020
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 188.8.131.52) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential...
The Global Oncology Partnering 2015-2020: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.